Here's a worst-case scenario: The data are analyzed by the FDA's standing arthritis advisory committee, composed of well-intentioned doctors who desperately need painkillers to give their patients.
In a development that greatly bolsters its standing in the cystic fibrosis market, Vertex Pharmaceuticals late yesterday released data showing a combination of its existing Kalydeco treatment and an experimental medication called VX-661 greatly improved patient breathing.
To separate the effects of money from the effects of diet and choice of drink, Dr Barefoot, Dr Gronbaek and their team analysed data from a group of subjects who possessed similar financial means and social standing.
This long-standing challenge for customers is aggravated by dramatic increases in cost and complexity amid a rising tide of sophisticated, data-intensive workloads in an increasingly interconnected world.